Dynamic Proteomic Change of Tumor and Immune Organs in an Immune-competent Hepatocellular Carcinoma Mouse Model

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2022 May 9

PMID 35530287

Authors

Jiaqi Jiao

Linlin Ji

Xianju Li

Zhan Gao

Guangshun Wang

Jun Qin

Yini Wang

Yi Wang

Affiliations

Soon will be listed here.

Abstract

Subcutaneous implantation of a human cancer cell line in immune-deficient mice (CDX) is a commonly used tool in preclinical studies for the assessment of potential anti-cancer drugs. As immunotherapy is transforming cancer treatment, tumor models in immunocompetent mice are necessary for us to understand the immune aspects of tumor biology. However, the systemic immune response to the implantation of cancer cells at proteome level is unclear. In this study, we characterized the dynamic proteomic changes of subcutaneous tumors and 5 immune organs (draining lymph node, mesenteric lymph node, spleen, thymus and marrow) at six time points after implantation using a Hepa1-6 derived allograft mouse model. Our data suggest that interaction of the implanted tumor cells with mouse immune system followed the trajectory of "tumor rejection" to "immune evasion" in that the tumor gained the ability to evade the immune system for growth. Furthermore, anti-PDL2 antibody was validated here as an optional immunotherapy strategy to inhibit the growth of Hepa1-6 subcutaneous tumors. These findings from our study provided valuable information for the understanding of tumor and immune interaction and shed light on the rational design for clinical cancer treatment and other preclinical experiments.

References

Park J, Kim H, Lee A, Seo Y, Kim I, Park E . Enlightening the Immune Mechanism of the Abscopal Effect in a Murine HCC Model and Overcoming the Late Resistance With Anti-PD-L1. Int J Radiat Oncol Biol Phys. 2020; 110(2):510-520. DOI: 10.1016/j.ijrobp.2020.12.031. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

Shirasaki T, Murai K, Honda M, Okada H, Innami Y, Yamada A . Establishment of liver tumor cell lines from atherogenic and high fat diet fed hepatitis C virus transgenic mice. Sci Rep. 2021; 11(1):13021. PMC: 8219799. DOI: 10.1038/s41598-021-92128-9. View

Guey B, Wischnewski M, Decout A, Makasheva K, Kaynak M, Sakar M . BAF restricts cGAS on nuclear DNA to prevent innate immune activation. Science. 2020; 369(6505):823-828. DOI: 10.1126/science.aaw6421. View

Droste M, Thakur B, Eliceiri B . Tumor-Derived Extracellular Vesicles and the Immune System-Lessons From Immune-Competent Mouse-Tumor Models. Front Immunol. 2021; 11:606859. PMC: 7772428. DOI: 10.3389/fimmu.2020.606859. View

Lakins M, Ghorani E, Munir H, Martins C, Shields J . Cancer-associated fibroblasts induce antigen-specific deletion of CD8 T Cells to protect tumour cells. Nat Commun. 2018; 9(1):948. PMC: 5838096. DOI: 10.1038/s41467-018-03347-0. View

Brown Z, Heinrich B, Greten T . Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. Nat Rev Gastroenterol Hepatol. 2018; 15(9):536-554. DOI: 10.1038/s41575-018-0033-6. View

Zhai L, Ladomersky E, Lenzen A, Nguyen B, Patel R, Lauing K . IDO1 in cancer: a Gemini of immune checkpoints. Cell Mol Immunol. 2018; 15(5):447-457. PMC: 6068130. DOI: 10.1038/cmi.2017.143. View

10.

Nie X, Chen W, Zhu Y, Huang B, Yu W, Wu Z . B7-DC (PD-L2) costimulation of CD4 T-helper 1 response via RGMb. Cell Mol Immunol. 2017; 15(10):888-897. PMC: 6207567. DOI: 10.1038/cmi.2017.17. View

11.

Olson B, Li Y, Lin Y, Liu E, Patnaik A . Mouse Models for Cancer Immunotherapy Research. Cancer Discov. 2018; 8(11):1358-1365. PMC: 8725605. DOI: 10.1158/2159-8290.CD-18-0044. View

12.

Shin S, Yang K, Lee M, Moon J, Son A, Kim Y . Manganese Ferrite Nanoparticles Enhance the Sensitivity of Hepa1-6 Hepatocellular Carcinoma to Radiation by Remodeling Tumor Microenvironments. Int J Mol Sci. 2021; 22(5). PMC: 7961905. DOI: 10.3390/ijms22052637. View

13.

Zhai Q, Qin J, Jin X, Sun X, Wang L, Du W . PADI4 modulates the invasion and migration of osteosarcoma cells by down-regulation of epithelial-mesenchymal transition. Life Sci. 2020; 256:117968. DOI: 10.1016/j.lfs.2020.117968. View

14.

Tanegashima T, Togashi Y, Azuma K, Kawahara A, Ideguchi K, Sugiyama D . Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. Clin Cancer Res. 2019; 25(15):4808-4819. DOI: 10.1158/1078-0432.CCR-18-3991. View

15.

Liu M, Qu Y, Teng X, Xing Y, Li D, Li C . PADI4‑mediated epithelial‑mesenchymal transition in lung cancer cells. Mol Med Rep. 2019; 19(4):3087-3094. PMC: 6423585. DOI: 10.3892/mmr.2019.9968. View

16.

Allen B, Hiam K, Burnett C, Venida A, DeBarge R, Tenvooren I . Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. Nat Med. 2020; 26(7):1125-1134. PMC: 7384250. DOI: 10.1038/s41591-020-0892-6. View

17.

Malovannaya A, Li Y, Bulynko Y, Jung S, Wang Y, Lanz R . Streamlined analysis schema for high-throughput identification of endogenous protein complexes. Proc Natl Acad Sci U S A. 2010; 107(6):2431-6. PMC: 2823922. DOI: 10.1073/pnas.0912599106. View

18.

De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu S, Piaggio E . Humanized Mice for the Study of Immuno-Oncology. Trends Immunol. 2018; 39(9):748-763. DOI: 10.1016/j.it.2018.07.001. View

19.

Liu M, Wang X, Wang L, Ma X, Gong Z, Zhang S . Targeting the IDO1 pathway in cancer: from bench to bedside. J Hematol Oncol. 2018; 11(1):100. PMC: 6090955. DOI: 10.1186/s13045-018-0644-y. View

20.

Whiteside T, Mandapathil M, Szczepanski M, Szajnik M . Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs. Bull Cancer. 2011; 98(2):E25-31. DOI: 10.1684/bdc.2010.1294. View